Neurology Central

The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson’s disease treatment


The introduction of dopamine agonists was a welcome development in the treatment of Parkinson’s disease. However, their history has been somewhat checkered with concerns about their side effects including sudden onset of sleep and ‘sleep attacks’ the development of fibrotic side effects with ergot-derived agents; and most recently, the emergence of impulse control disorders.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.